Vaccino Reithera, Ippolito: “Italy returns to investing in research”

“I hope that a real investment will be made to increase the country’s production capacity. There may be different forms and sources of financing but it is important that we go back to developing experiments and research”. The scientific director of Inmi Spallanzani of Rome, Giuseppe Ippolito, said this to Adnkronos Salute, commenting on the decision of the Court of Auditors to stop part of the funding foreseen for the development of the ‘Italian’ vaccine of the ReiThera company. “I agree with what ISS president Silvio Brusaferro said on this matter: it is important to have a national platform that relies on a technology developed by Italians and built in our country – he added -. In the last 20 years we have lost our skills we had, we have been leaders in some sectors developing, in the past, drugs against TB and today the production of the initial phase for the anti-hepatitis C drug “. On the risk that the ReiThera vaccine, to whose Phase I trial has contributed even Spallanzani, may not come to light, Ippolito specifies that “the company that has economic availability and has had the opportunity to be a forerunner must speak on this aspect because it has relied on an already validated platform and have great technological capabilities. Phase 2 of the trial – he concludes – was successfully completed on 900 patients and within two months we will have the first results. i will go to Phase III “.